2016
Autologous Stem Cell Mobilization in the Age of Plerixafor
Cooper DL, Medoff E, Patel N, Baker J, Pratt K, Foss F, Seropian SE, Perreault S, Wu Y. Autologous Stem Cell Mobilization in the Age of Plerixafor. Clinical Lymphoma Myeloma & Leukemia 2016, 16: 411-416. PMID: 27245311, DOI: 10.1016/j.clml.2016.04.007.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntigens, CD34BenzylaminesCyclamsFemaleGraft SurvivalGranulocyte Colony-Stimulating FactorHematopoietic Stem Cell MobilizationHematopoietic Stem Cell TransplantationHematopoietic Stem CellsHeterocyclic CompoundsHumansLymphomaMaleMiddle AgedMultiple MyelomaTreatment OutcomeWorkflowConceptsStem cell mobilizationCell mobilizationPlerixafor useG-CSFAutologous stem cell transplantationAutologous stem cell mobilizationGranulocyte-colony stimulating factor (G-CSF) mobilizationDose of plerixaforLess platelet transfusionsStem cell transplantationCD34 cells/Treatment of myelomaCells/High-risk factorsEnough stem cellsStem cellsHematologic tolerancePosttransplantation therapyRelapsed lymphomaPlatelet transfusionsCell transplantationRisk factorsFactor mobilizationPatientsPlerixafor
2012
Successful collection and engraftment of autologous peripheral blood progenitor cells in poorly mobilized patients receiving high‐dose granulocyte colony‐stimulating factor
Cooper DL, Proytcheva M, Medoff E, Seropian SE, Snyder EL, Krause DS, Wu Y. Successful collection and engraftment of autologous peripheral blood progenitor cells in poorly mobilized patients receiving high‐dose granulocyte colony‐stimulating factor. Journal Of Clinical Apheresis 2012, 27: 235-241. PMID: 22566214, DOI: 10.1002/jca.21232.Peer-Reviewed Original ResearchConceptsHigh-dose G-CSFAutologous HPC transplantationHematopoietic progenitor cellsG-CSFHPC transplantationProgenitor cellsAutologous peripheral blood progenitor cell collectionHigh-dose granulocyte colony-stimulating factorAutologous peripheral blood progenitor cellsRetrospective medical record reviewPeripheral blood progenitor cell collectionPeripheral blood progenitor cellsMedical record reviewGranulocyte-colony stimulating factorGranulocyte colony-stimulating factorBlood progenitor cellsEfficacy of mobilizationProgenitor cell harvestsProgenitor cell collectionColony-stimulating factorPlatelet engraftmentRecord reviewSafety profileGood mobilizersPeripheral blood
2011
Late Afternoon Dosing of Plerixafor for Stem Cell Mobilization: A Practical Solution
Cooper DL, Pratt K, Baker J, Medoff E, Conkling-Walsh A, Foss F, Snyder E, Yen W, Seropian SE. Late Afternoon Dosing of Plerixafor for Stem Cell Mobilization: A Practical Solution. Clinical Lymphoma Myeloma & Leukemia 2011, 11: 267-272. PMID: 21658654, DOI: 10.1016/j.clml.2011.03.014.Peer-Reviewed Original ResearchConceptsStem cell mobilizationEnough stem cellsMultiple myelomaCell mobilizationG-CSFPrevious mobilizationGranulocyte colony-stimulating factorNon-Hodgkin lymphomaStem cellsG-CSF mobilizationColony-stimulating factorPrevious chemotherapyPrevious therapyMobilization failurePoor mobilizationEvening injectionsCD34 countHigh riskPatientsPlerixaforCell countCost-effective useMyelomaLenalidomideChemotherapy
2009
Stem Cell Mobilization Using 5 Pm Dosing of Plerixafor.
Cooper D, Baker J, Medoff E, Pratt K, Conkling-Walsh A, Snyder E, Seropian S, Foss F. Stem Cell Mobilization Using 5 Pm Dosing of Plerixafor. Blood 2009, 114: 4233. DOI: 10.1182/blood.v114.22.4233.4233.Peer-Reviewed Original ResearchStem cell mobilizationPM dosingPoor mobilizersMultiple myelomaCell mobilizationG-CSFStem cell mobilizing agentsPrior mobilizationGerm cell tumorsOff-label useStem cellsStem cell collectionAutologous stem cellsEvening dosingFour patientsMedian WBCCell tumorsLabel usePlatelet recoveryPivotal studiesMedian numberPatientsCD34 cellsCell collectionDosing
2003
A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents
Lerro KA, Medoff E, Wu Y, Seropian SE, Snyder E, Krause D, Cooper DL. A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents. Bone Marrow Transplantation 2003, 32: 1113-1117. PMID: 14647264, DOI: 10.1038/sj.bmt.1704286.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsBlood Cell CountCombined Modality TherapyCyclophosphamideDatabases, FactualDexamethasoneDoxorubicinFemaleFeverGranulocyte Colony-Stimulating FactorHematopoietic Stem Cell MobilizationHumansLeukapheresisMaleMiddle AgedMultiple MyelomaNeutropeniaPeripheral Blood Stem Cell TransplantationRetrospective StudiesTransplantation, AutologousVincristineConceptsMultiple myelomaEnough stem cellsCells/Autologous stem cell rescueFever/neutropeniaG-CSF beginningStem cell rescueHigh-dose chemotherapyPotential transplant candidatesMultiple myeloma patientsStem cell collectionStem cell toxicityStem cellsAggressive chemotherapyInitial therapyTransplant candidatesAgent therapyConsecutive patientsExcessive morbidityMyeloma patientsCell mobilizationCell rescuePatientsG-CSFCell collection